Case Report

Clinical Rheumatology

, Volume 25, Issue 1, pp 83-87

First online:

Familial Mediterranean fever responds well to infliximab: single case experience

  • Salih OzgocmenAffiliated withDivision of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University Email author 
  • , Levent ÖzçakarAffiliated withDepartment of Physical Medicine and Rehabilitation, Hacettepe University Medical School
  • , Ozge ArdicogluAffiliated withDivision of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University
  • , Ercan KocakocAffiliated withDepartment of Radiology, Faculty of Medicine, Firat University
  • , Arzu KayaAffiliated withDivision of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Firat University
  • , Adem KirisAffiliated withDepartment of Radiology, Faculty of Medicine, Firat University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The most common arthritic involvement in familial Mediterranean fever (FMF) is acute recurrent monoarthritis; however, sometimes spondyloarthropathy-like findings or typical ankylosing spondylitis may also ensue. Reported here is our favorable experience with infliximab in an FMF patient who had been resistant to colchicine and disease-modifying antirheumatic drugs (sulfasalazine and methotrexate) treatments. A 72-week follow-up of the patient yielded complete remission of the febrile abdominal episodes, and spondylitis responded well. The patient’s bilateral aseptic necrosis of the femoral head deteriorated and caused hip pain, discomfort, and disability. Overall, we believe that tumor necrosis factor (TNF) alpha has an important role in the disease pathogenesis and also that anti-TNF may represent a promising robust treatment alternative in FMF.

Keywords

Aseptic necrosis Familial Mediterranean fever Infliximab Spondylitis